| |
group
|
Pre-chemotherapy
|
Post-chemotherapy*
|
p-value
#
|
|---|
|
Tibial nerve
| | | | |
|
DML(ms)
|
Omega 3
|
16.53 (1.95)
|
17.59 (2.21)
|
.870
|
| |
Placebo
|
17.00 (2.16)
|
17.80 (3.10)
| |
|
a-CMAP(mV)
|
Omega 3
|
10.00 (5.18)
|
11.18 (6.35)
|
.149
|
| |
Placebo
|
11.38 (6.08)
|
10.68 (5.80)
| |
|
MCV(m/s)
|
Omega 3
|
46.38 (3.67)
|
45.16 (4.24)
|
.359
|
| |
Placebo
|
46.24 (5.08)
|
46.03 (6.65)
| |
|
Peroneal nerve
| | | | |
|
DML(ms)
|
Omega 3
|
14.16 (1.80)
|
14.97 (2.53)
|
.209
|
| |
Placebo
|
14.85 (3.18)
|
14.91 (2.37)
| |
|
a-CMAP(mV)
|
Omega 3
|
6.20 (6.68)
|
4.43 (3.26)
|
.549
|
| |
Placebo
|
5.51 (3.41)
|
3.83 (3.15)
| |
|
MCV(m/s)
|
Omega 3
|
46.13 (3.32)
|
45.87 (4.75)
|
.106
|
| |
Placebo
|
46.46 (5.24)
|
42.38 (9.90)
| |
|
Ulnar nerve
| | | | |
|
DML(ms)
|
Omega 3
|
9.48 (.74)
|
9.67 (.86)
|
.439
|
| |
Placebo
|
9.67 (.98)
|
9.60 (1.29)
| |
|
a-CMAP(mV)
|
Omega 3
|
17.29 (12.95)
|
14.25 (3.79)
|
.256
|
| |
Placebo
|
13.80 (3.53)
|
13.29 (4.73)
| |
|
MCV(m/s)
|
Omega 3
|
57.30 (5.18)
|
55.82 (6.35)
|
.706
|
| |
Placebo
|
55.80 (4.90)
|
53.19 (7.29)
| |
- DML, distal motor latency; a-CMAP, amplitude of compound muscle action potential; MCV, motor conduction velocity.
- * One month after the cessation of chemotherapy.
- # p value is reported based on the analysis of covariance.
